These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 35799269)

  • 1. Identification of a cytokine-dominated immunosuppressive class in squamous cell lung carcinoma with implications for immunotherapy resistance.
    Yang M; Lin C; Wang Y; Chen K; Zhang H; Li W
    Genome Med; 2022 Jul; 14(1):72. PubMed ID: 35799269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of cytokine-predominant immunosuppressive class and prognostic risk signatures in glioma.
    Tian Z; Yang Z; Jin M; Ding R; Wang Y; Chai Y; Wu J; Yang M; Zhao W
    J Cancer Res Clin Oncol; 2023 Nov; 149(14):13185-13200. PubMed ID: 37479756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of immunosuppressive signature subtypes and prognostic risk signatures in triple-negative breast cancer.
    Ding R; Wang Y; Fan J; Tian Z; Wang S; Qin X; Su W; Wang Y
    Front Oncol; 2023; 13():1108472. PubMed ID: 37377907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analyses of a CD8
    Chen L; Weng Y; Cui X; Li Q; Peng M; Song Q
    BMC Bioinformatics; 2023 Jun; 24(1):238. PubMed ID: 37280525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
    Exposito F; Redrado M; Houry M; Hastings K; Molero-Abraham M; Lozano T; Solorzano JL; Sanz-Ortega J; Adradas V; Amat R; Redin E; Leon S; Legarra N; Garcia J; Serrano D; Valencia K; Robles-Oteiza C; Foggetti G; Otegui N; Felip E; Lasarte JJ; Paz-Ares L; Zugazagoitia J; Politi K; Montuenga L; Calvo A
    Cancer Res; 2023 Aug; 83(15):2513-2526. PubMed ID: 37311042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
    Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
    Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
    Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
    J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of SLC2A1 as a predictive biomarker for survival and response to immunotherapy in lung squamous cell carcinoma.
    Hao B; Dong H; Xiong R; Song C; Xu C; Li N; Geng Q
    Comput Biol Med; 2024 Mar; 171():108183. PubMed ID: 38422959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer.
    Gao Y; Stein MM; Kase M; Cummings AL; Bharanikumar R; Lau D; Garon EB; Patel SP
    Cancer Immunol Immunother; 2023 Feb; 72(2):339-350. PubMed ID: 35881197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
    Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
    Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 and CD47 co-expression predicts survival and enlightens future dual-targeting immunotherapy in non-small cell lung cancer.
    Yang Z; Peng Y; Guo W; Xu J; Li L; Tian H; Li R; Liu L; Tan F; Gao S; He J
    Thorac Cancer; 2021 Jun; 12(11):1743-1751. PubMed ID: 33979899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
    Shang X; Li J; Wang H; Li Z; Lin J; Chen D; Wang H
    Int Immunopharmacol; 2020 Nov; 88():106864. PubMed ID: 32866782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
    Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
    Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
    [No Abstract]   [Full Text] [Related]  

  • 15. Prediction of lung squamous cell carcinoma immune microenvironment and immunotherapy efficiency with pyroptosis-derived genes.
    Deng X; Wang Z; Luo Y; Li Z; Chen L
    Medicine (Baltimore); 2022 Sep; 101(37):e30304. PubMed ID: 36123889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma.
    Duan J; Zhang Y; Chen R; Liang L; Huo Y; Lu S; Zhao J; Hu C; Sun Y; Yang K; Chen M; Yu Y; Ying J; Huang R; Ma X; Leaw S; Bai F; Shen Z; Cai S; Gao D; Wang J; Wang Z
    Cell Rep Med; 2023 Dec; 4(12):101302. PubMed ID: 38052215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
    Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
    Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Exploration of the Perturbation of PKIG in Lung Squamous Cell Carcinoma and the Role in Tumor Microenvironment Based on Bioinformatics Method].
    Liu Q; Li H; Li B; Ren M; Li Z; Chen Y; Zheng Z; Meng Y; Feng H
    Zhongguo Fei Ai Za Zhi; 2023 Jul; 26(7):523-537. PubMed ID: 37653016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of tumour-infiltrating myeloid subsets associated with overall survival in lung squamous cell carcinoma.
    Lu J; Duan Y; Liu P; He X; Yang Y; Zhang R; Weng L
    J Pathol; 2023 Jan; 259(1):21-34. PubMed ID: 36178315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
    Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
    Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.